RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q2 2024
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 0 | 306.62M | $17.19B | +5 | −4 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | — |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | — | — |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | — | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | — |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | — | 58.59M | $1.54B | — | — |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 11.97M | — | $315.65M | 1.2% | n/c | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 10.93M | — | $288.28M | 0.5% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (pasif) | 6.85M | — | $180.30M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasif) | 6.85M | — | $180.30M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Norges Bank ✦ (pasif) | 4.81M | — | $126.82M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 2.35M | — | $61.98M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 2.06M | — | $54.26M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 945.84K | — | $24.94M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 940.03K | — | $24.79M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 270.45K | — | $7.13M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 238.99K | — | $6.30M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 57.40K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Wellington Management ✦ | 57.40K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Wellington Management ✦ | 57.40K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 33.61K | — | $886,348 | 0.0% | n/c | 1 | SEC ↗ |
"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Tidak ada keluar yang terlacak kuartal ini. |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 583 pemegang, 354.58M saham, $16.55B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.
Penjualan di pasar terbuka (S)
Officer · 100.00K lbr · $6.00M
Officer · 9.23K lbr · $540,752
Officer · 1.77K lbr · $104,799
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi
18.7% dari kelas · Lihat pengajuan SEC asli ↗
4.8% dari kelas · Lihat pengajuan SEC asli ↗